Hematology
2211 articles · 38 journals
Journals in this subcategory (38)
- Annals of Hematology · Springer Nature (468)
- Blood Research · Springer Nature (143)
- Annals of Thoracic Surgery Short Reports · Elsevier (114)
- Journal of Thrombosis and Haemostasis · Elsevier (110)
- Blood Advances · Elsevier (101)
- Research and Practice in Thrombosis and Haemostasis · Elsevier (99)
- British Journal of Haematology · Wiley (90)
- Blood · Elsevier (85)
- Thrombosis Research · Elsevier (82)
- Vox Sanguinis · Wiley (80)
- European Journal of Haematology · Wiley (79)
- Haemophilia · Wiley (73)
- Clinical Lymphoma, Myeloma & Leukemia · Elsevier (71)
- Transfusion and Apheresis Science · Elsevier (69)
- Radiotherapy & Oncology · Elsevier (66)
- Annals of Oncology · Elsevier (64)
- Transfusion · Wiley (64)
- American Journal of Hematology · Wiley (58)
- Hematology/Oncology Clinics of North America · Elsevier (50)
- Transfusion Medicine Reviews · Elsevier (39)
- Seminars in Hematology · Elsevier (37)
- Seminars in Oncology · Elsevier (29)
- The Lancet Haematology · Elsevier (28)
- Transfusion Medicine · Wiley (28)
- Experimental Hematology · Elsevier (22)
- HemaSphere · Wiley (17)
- Thrombosis Update · Elsevier (15)
- Journal of Clinical Apheresis · Wiley (12)
- Blood Cancer Journal · Springer Nature (7)
- Leukemia · Springer Nature (7)
- Ca-A Cancer Journal for Clinicians · Wiley (4)
- Experimental Hematology & Oncology · Springer Nature (0)
- Indian Journal of Hematology and Blood Transfusion · Springer Nature (0)
- International Journal of Clinical Oncology · Springer Nature (0)
- International Journal of Hematology · Springer Nature (0)
- Medical Oncology · Springer Nature (0)
- Thrombosis Journal · Springer Nature (0)
- memo - Magazine of European Medical Oncology · Springer Nature (0)
- Real‐World Efficacy and Safety of Standard‐of‐Care Chimeric Antigen Receptor T‐Cell (CART) and Bispecific T‐Cell Engager (TCE) Therapies in Relapsed/Refractory Multiple Myeloma (RRMM)
- Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH): An Algorithmic Approach in an Era of New Treatments
- Association of the PROC rs146922325 variant with venous thrombosis in a Taiwanese population
- Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability
- Neutropenia in adult patients with thalassemia receiving deferiprone: a 10-year experience from a large thalassemia cohort
- Targeting CDK7 to overcome hypomethylating agent resistance in acute myeloid leukemia
- Feasibility of therapeutic drug monitoring of asparaginase across multiple formulations in pediatric acute lymphoblastic leukemia
- G6PD activity patterns and a stable adjusted male median derived from 16 years of clinical laboratory data
- Clonal hematopoietic mutations as a predictor of adverse outcomes in cytopenic patients with chronic kidney disease
- Deciphering the circadian signature in acute myeloid leukemia: NPAS2 downregulation as a master predictive feature
- Myeloid-lineage blasts with histiocytoid differentiation in TP53 mutated acute myeloid leukemia: a deceptive morphologic overlap with mature malignant histiocytic neoplasms
- 2026 Korean expert recommendations for the use of thrombopoietin receptor agonists in severe aplastic anemia
- Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience
- Response-adapted lenalidomide–dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study
- Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review
- Recent advances in the treatment of FLT3-mutated acute myeloid leukemia
- Primary breast follicular lymphoma without a BCL2 rearrangement: insights into extranodal lymphoma biology
- Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65–75 years: a real-world study
- Novel treatment strategies in acute myeloid leukemia
- Cross-cultural validation and reliability of the Korean version of the Haemophilia Activities List
-
Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention
Abstract Chimeric antigen receptor (CAR) T-cell therapy is an established treatment for relapsed or refractory B-cell malignancies. Despite therapeutic success, infectious complications remain a major contributor to non-relapsed...
- Allogeneic stem cell transplantation for myelofibrosis in the modern era: Single-center outcomes with DIPSS risk stratification
-
Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations
Abstract Background Gilteritinib is an established FLT3 inhibitor used to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring FLT3 mutations. Prior studies have predominantly evaluated gilteritinib as...
- A mitochondrial-based prognostic score for risk stratification in acute myeloid leukemia
-
The role of impaired bone marrow Tregs in hematopoietic stem cell depletion for pediatric aplastic anemia probably involves immune privilege
Abstract Purpose An immune-mediated pathogenesis has been postulated for aplastic anemia (AA), and impaired Tregs and other immune abnormalities have been identified in patients with AA. However, the process by which abnormal immunity...
- A strategic approach to managing Immune Effector Cell-Associated Hematotoxicity (ICAHT) during chimeric antigen receptor T-cell therapy
-
Dynamic, anthracycline-induced chromatin alterations enable ALDH1 expression as a mechanism of inducible leukemia resistance development
Abstract The evolution of acute myeloid leukemia (AML) cells toward developing drug resistance, which eventually leads to relapse, involves the convergence of their chromatin compaction status toward a pattern that is distinctive of...
-
Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response
Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma. The non-germinal center B-cell-like (non-GCB) subtype is associated with a poor prognosis and reduced response rates...
-
Enlarged splenic volume predicts poor survival and is associated with inflammatory imbalance in patients with diffuse large B-cell lymphoma
Abstract Purpose The spleen plays a significant role in innate and adaptive immunity. We aimed to evaluate the prognostic significance of the splenic volume in patients with diffuse large B-cell lymphoma (DLBCL), research on which is...
-
Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches
Abstract Purpose Multiple myeloma (MM) is a hematologic malignancy associated with a poor prognosis. MM-derived mesenchymal stromal cells (MM-MSCs) contribute to disease progression by creating a supportive stromal microenvironment for...